Yes, people have died from asthma, including children and adults. Learn about socioeconomic variables and comorbid factors in ...

For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024.

Cases of the infection human metapneumovirus (HMPV) have caused some concern among experts amid rising levels in the UK and ...

Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...